Investment
Features
FeesSafety
Academy
More
Pluang+

Ethereum plans quantum-safe, scalable upgrades by 2030 with advanced proof-of-stake and zero-knowledge proofs.

Protocol Fundamentals
27 Sep 2026
Tokenpost
View Source
Bullish
Ethereum plans quantum-safe, scalable upgrades by 2030 with advanced proof-of-stake and zero-knowledge proofs.

Ethereum co-founder Vitalik Buterin outlined a vision for the network by 2030 to become a cryptographic computing system with enhanced security and scalability. The plan includes using PeerDAS data sampling and SNARK verification to reduce node workload, evolving proof-of-stake to a more optimized form, and integrating zero-knowledge proofs at the base layer. Future upgrades aim for quantum resistance across execution, consensus, and data layers by 2029, preparing for potential quantum threats around 2030. This roadmap is a technical direction, not a fixed upgrade schedule, and could change how developers build applications on Ethereum.

Ethereum's future vision as a cryptographic computer is presented here with Pluang's market snapshot for major cryptocurrencies as of Sep 27, 2026 21:03 WIB: Among 50 priced assets, 28 rose and 21 fell. SNX gained 2.63% to Rp4.768 but saw mostly sell orders (89% Sell / 11% Buy) and a typical hold time of 70 days. In contrast, SAND and VET both declined by 2.51%, priced at Rp801 and Rp168 respectively, with SAND favored by buyers (56% Buy) and a longer hold time of 123 days, while VET had more sell orders (60% Sell) and the longest hold time of 147 days.

More News

Zcash (ZEC) price drops 2% in an hour amid $700K long liquidations on major exchanges

Zcash (ZEC) price drops 2% in an hour amid $700K long liquidations on major exchanges

Zcash (ZEC) experienced a 2.01% price drop within an hour on September 27, falling from $1,650 to $1,617 on Binance's spot market. Despite this decline, ZEC remains up nearly 5% over the past 24 hours. During the same hour, long liquidations totaled ...

Market News
Bearish
4 hours ago
United Therapeutics rated Buy despite revenue dips; key growth from Tyvaso DPI and upcoming FDA reviews.

United Therapeutics rated Buy despite revenue dips; key growth from Tyvaso DPI and upcoming FDA reviews.

United Therapeutics is rated Buy with a base valuation of $535 per share, despite recent revenue declines caused by competition from Liquidia's Yutrepia. The company's main growth driver remains Tyvaso DPI, with declines limited to older drug formula...

Analyst Insights
Bullish
4 hours ago
GoDaddy shares rise as Gen Digital's takeover bid report causes its stock to plunge

GoDaddy shares rise as Gen Digital's takeover bid report causes its stock to plunge

Shares of Gen Digital fell over 12% after reports of a preliminary takeover approach for GoDaddy, whose shares rose nearly 5%. The market reaction suggests skepticism about Gen Digital's ability to finance the deal, given their similar market values ...

Market News
Neutral
4 hours ago
Ethereum plans major upgrades by 2030 to boost security and scalability, but $10K price seems unlikely by 2026.

Ethereum plans major upgrades by 2030 to boost security and scalability, but $10K price seems unlikely by 2026.

Ethereum co-founder Vitalik Buterin has revealed a bold roadmap aiming for major technological upgrades by 2030, including advanced cryptography and a protocol redesign to improve scalability, privacy, and security. Despite these ambitious plans, mar...

Protocol Fundamentals
Bullish
4 hours ago
IBM upgraded to Buy with 17% upside as software revenue and growth outlook improve

IBM upgraded to Buy with 17% upside as software revenue and growth outlook improve

IBM has been upgraded to a Buy rating with a price target of $264.85 by 2027, reflecting a 17% potential upside. The upgrade is driven by strong recurring software revenue, which constitutes 80% of annual software sales and grew 8% to $24.6 billion i...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App